Juvenescence Chairman explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.
by Danny Sullivan – Longevity Technology
In a few short weeks, The Longevity Week returns, bringing with it a host of compelling events and conferences both in-person and online. Also returning is Master Investor’s one-day masterclass, Investing in the Age of Longevity, which provides investors with insight into the fundamentals of longevity science, where and how to invest, and the opportunity to meet the founders of investable longevity companies. Confirmed speakers already include BioAge CEO Kristen Fortney and Juvenescence CFO David Gill, as well as Fiona Miller of quadraScope Venture Fund, Dani Saurymper of Pacific Asset Management, and our very own editor in chief, Phil Newman.
Longevity.Technology: We are on the verge of a lifespan revolution – in the next 30 years, life expectancy is going to rise to between 110 and 120 and it’s time to get ahead of the challenges and capitalise on the opportunities. Longevity arguably presents the greatest investment opportunity of all time as aging affects everybody, everywhere. But don’t just take our word for it. We spoke to British billionaire Jim Mellon, Chairman of longevity biotech company Juvenescence, to find out why he believes the time is right to invest in longevity.
It’s safe to say that 2022 has been a significant year from a longevity investment perspective.
